Open AccessQuantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry
Author(s) -
Richter Annika,
Fichtner Alexander,
Joost Jasmin,
Brockmeyer Philipp,
Kauffmann Philipp,
Schliephake Henning,
HammersteinEquord Alexander,
Kueffer Stefan,
Urlaub Henning,
Oellerich Thomas,
Ströbel Philipp,
Bohnenberger Hanibal,
Bremmer Felix
Publication year - 2022
Publication title -
the journal of pathology: clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.849
H-Index - 21
ISSN - 2056-4538
DOI - 10.1002/cjp2.244
Subject(s) - immunohistochemistry , head and neck squamous cell carcinoma , pathology , biomarker , medicine , lung , cell , cancer research , oncology , biology , head and neck cancer , cancer , biochemistry , genetics
The differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important for the prognosis and therapy of the affected patient. By using high‐resolution mass spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 proteins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. Of those, CAV1, CAV2, LGALS1, LGALS7, CK19, and UGDH were tested by immunohistochemistry on 194 tissue samples (98 lung and 96 HNSCCs). The combination of CAV1 and LGALS7 was able to distinguish the origin of the squamous cell carcinoma with high accuracy (area under the curve 0.876). This biomarker panel was tested on a cohort of 12 clinically classified lung tumours of unknown origin after HNSCC. Nine of those tumours were immunohistochemically classifiable.